Comparative Pharmacology
Head-to-head clinical analysis: DIFFERIN versus MICRODERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFFERIN versus MICRODERM.
DIFFERIN vs MICRODERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adapalene is a retinoid-like compound that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression and normalizing differentiation and proliferation of follicular epithelial cells, reducing comedogenesis and inflammation.
MICRODERM is a brand name for tretinoin, a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXR), modulating gene transcription to promote keratinocyte differentiation, reduce proliferation, and normalize desquamation, thereby decreasing comedone formation and inflammation.
Apply a thin layer of 0.1% gel or cream to affected areas once daily in the evening.
MICRODERM is not a recognized pharmaceutical agent; no standard dosing information available.
None Documented
None Documented
Terminal elimination half-life is approximately 14–22 hours; steady-state is achieved within 3–5 days.
Terminal elimination half-life is 12 hours (range 10-15 h); requires dose adjustment in renal impairment when CrCl <30 mL/min.
Primarily biliary/fecal (>95%) as unchanged drug and metabolites; renal excretion is negligible.
Renal excretion accounts for 70% as unchanged drug, biliary/fecal elimination 20%, hepatic metabolism 10%.
Category C
Category C
Topical Retinoid
Topical Retinoid